Compass Therapeutics Q2 EPS $(0.13) Misses $(0.11) Estimate
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 7.14 percent increase over losses of $(0.14) per share
Compass Therapeutics lost more money per share than experts expected, though it's doing slightly better than last year. When a company loses more than people predicted, it can make investors nervous and worth watching to see if the company can improve.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.